The current leaders - who market and sell the two commercially approved obesity drug molecules, semaglutide and tirzepatide, ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Danish drug manufacturer Novo Nordisk is partnering with California-based biotech Septerna to develop the latest pills to ...

Novo Nordisk is moving forward with plans to develop oral obesity drugs through a new partnership, which comes as longtime CEO Lars Fruergaard Jørgensen prepares to step down. The drugmaker launched a ...

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big ...

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it ...

Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight ...

Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...

Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk. In the meantime, a search for Jørgensen’s successor is ongoing. Novo Nordisk says the leadership transition is “made in ...

Lars Fruergaard Jørgensen, the chief executive of once-highflying Danish drug manufacturer Novo Nordisk, is stepping down after eight years in the role, the maker of the drugs Ozempic and Wegovy ...